Favoring the MHC-II restricted tumor antigen recognition by anti-tumor CD4+ TH cells from one side and blocking their functional activity by PD-1/PD-L1 interaction from the other side could partially explain the lack of clear beneficial outcomes in terms of survival in MHC-II-positive cancers (54). This evidence concerns the gene CD4 and cancer.